Early findings from the ongoing phase 1/2 AMPLIFY-7P trial suggest that the investigational vaccine ELI-002 7P could represent a breakthrough in treating pancreatic ductal adenocarcinoma (PDAC), one of the most challenging cancers to treat. The vaccine, designed to target multiple $KRAS$ mutations, has shown a strong and consistent ability to stimulate the immune system in

Researchers have created a promising new combination immunotherapy that could improve treatment for ovarian cancer, a disease that often resists standard immunotherapies. The study combines two immune-based treatments to produce a stronger and longer-lasting anti-tumor response. The first component uses engineered T cells that specifically target the folate receptor alpha, a protein found in abundance

Toripalimab-tpzi (Loqtorzi) has been approved as the first and only immunotherapy for recurrent, unresectable, or metastatic nasopharyngeal carcinoma (NPC). It can be used in combination with cisplatin and gemcitabine as a first-line treatment for metastatic or recurrent locally advanced NPC, or as a single drug for patients whose disease has progressed after platinum-based chemotherapy. The

Montanide ISA-51 is a water-in-oil emulsion adjuvant derived from Freund’s incomplete adjuvant and is designed to enhance immune responses in cancer vaccines with lower toxicity. It works by forming an oil depot at the injection site, allowing slow and sustained release of the antigen for prolonged immune stimulation. This process recruits immune cells like dendritic